Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Staar new-tech IOLs

This article was originally published in The Gray Sheet

Executive Summary

Staar Surgical's Afinity Collamer Aspheric Single Piece and Elastimide Silicone intraocular lenses join the class of new technology IOLs that qualify for $50 extra payment from CMS based on improved outcomes compared with traditional lenses, the company announces July 24. The bonus payments will expire Feb. 26, 2011. Other lenses with the same special designation for reducing spherical aberrations include AMO's Tecnis, Alcon's Acrysof IQ, Bausch & Lomb's Sofport and Staar's Afinity Collamer Aspheric Three Piece (1"The Gray Sheet" March 24, 2008, In Brief). The Elastimide lens is available immediately, while the Single Piece lens will launch later this quarter, Staar says

You may also be interested in...



Staar lens wins CMS new technology IOL recognition

Medicare will provide an additional reimbursement of $50 per lens when Staar Surgical's Afinity Collamer Aspheric foldable intraocular lens is provided to a cataract patient in an ambulatory surgical center, following the lens' designation as a new technology intraocular lens by CMS, announced March 17. To receive NTIOL recognition, an IOL must be FDA-approved with labeling and advertising consistent with the specific claim for which CMS approval is being sought, and the IOL must provide measurable, clinically meaningful improved patient outcomes over other available IOLs. The Staar Afinity IOL, which has been cleared for enhanced reimbursement through Feb. 26, 2011, reduces spheric aberrations to improve visual acuity, Staar says

New EU Filings

Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches

UK switch specialist Maxwellia delivers two “me too” reclassifications in the area of women's health: Evana Heavy Period Relief and Ultravana Period Pain Relief. 

Latest Headlines
See All
UsernamePublicRestriction

Register

MT026389

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel